Consensus recommendations on the diagnosis and treatment of hepatitis C virus infection in sub-Saharan Africa

Abstract

Sub-Saharan Africa has a high burden of hepatitis C virus (HCV) infection. Therefore, 10 experts from Africa convened, reviewed the literature, and provided recommendations to optimize the diagnosis; management; and pre-, on- and post-treatment assessment of HCV infection in Africa. The panel recommended initial anti-HCV testing, followed by qualitative HCV RNA assay/core antigen testing for HCV diagnosis. The panel suggested that genotype testing may help in treatment selection; however, use of pan-genotypic regimens (sofosbuvir-velpatasvir) may obviate the need for genotyping. The recommended pre-treatment assessments include tests for hepatic/renal function; hepatitis B surface antigen; HIV; non-invasive fibrosis assessment; and testing for hepatocellular carcinoma. The panel provided an overview of the use of available antiviral agents (sofosbuvir, ledipasvir, daclatasvir and velpatasvir) for treatment of HCV GT1–GT6 infections. This consensus document may help guide clinicians to effectively use the available antiviral agents and optimize diagnosis and treatment of HCV infection in Africa.

Keywords: hepatitis C virus, treatment, consensus, sub-Saharan Africa

Introduction

Hepatitis C virus (HCV) belongs to the genus *Hepacivirus* of the family *Flaviviridae* and is classified into 6 major genotypes (GT1–GT6). An expanded classification of HCV reveals a new genotype, GT7. A similar HCV prevalence pattern, with high rates in the Middle Africa region, and low rates in Southern Africa, was reported in another systematic review and meta-analysis of 184 nation-level estimations across Africa. Other systematic reviews and meta-analyses on the prevalence of HCV infection across countries in West and Central sub-Saharan Africa have also revealed a high seroprevalence of HCV in these regions.
In the Polaris Observatory report, the GT distribution was analyzed for 115 countries, and it was noted that about 44% of global HCV cases were GT1, followed by GT3 (25%) and GT4 (15%). In Africa, the most prevalent GT in the Central, West, Southern and East sub-Saharan regions was noted to be GT4, followed by GT1, GT5, and GT4, respectively. A wide variation in the GT distribution was noted within some regions in Africa. In the West sub-Saharan African belt, while regions such as Nigeria had a high prevalence of GT1; others including Ghana, The Gambia, Guinea Bissau and Burkina Faso had a high prevalence of GT2; Chad had a high prevalence of GT4; and Cameroon had high prevalence of both GT1 and GT4.6

In addition to the diversity in HCV prevalence and GT distribution across various regions of Africa, high genetic diversity has been observed in the most common genotype of the region, GT4.10 Furthermore, robust epidemiological and GT prevalence data are lacking, as all the countries in the region have not contributed to the national GT distribution data in most of the available large-scale epidemiological studies.5,10 In the absence of robust prevalence data which forms the very basis for the development of healthcare policy, efficient management of the disease cannot be achieved.7,10,11

Several other unmet needs and challenges have been reported in the literature on the management of HCV infection in Africa, including: (1) lack of proper surveillance, resulting in inaccurate estimation of the burden of HCV infection;12 (2) emergence of resistant GT 5 HCV infections;13 (3) emergence of GT7;14 (4) dearth of cost-effective, rapid diagnostic tests; (5) reduced efforts from patient’s end to access HCV treatment due to threat of stigmatization, and discrimination;15 (6) licensing, patent and cost aspect of direct-acting antiviral (DAA) therapy;16 (7) use of unlicensed generics with low efficacy;17,18 (8) lack of universal treatment coverage for HCV patients;19 and (9) non-responsiveness of patients to DAA treatment.20 Development of structured nation-specific HCV treatment guidelines/strategies has also been cited a crucial need of the hour in the African region.12 In this context, it is pertinent to mention that there is no clear latest consensus on the diagnosis, management, and monitoring of HCV infection, specific to the African region. Hence, the objective of the current consensus document is to guide clinicians on the diagnosis and management of chronic HCV infection in the resource-limited settings of Africa to ensure optimal clinical outcomes.

### Methodology of consensus development

In April 2018, a panel of ten experts in the field of hepatology from Africa convened to review the updated literature on the management of HCV infection and provide recommendations to optimize the:

- Diagnosis of HCV infection
- Use of cost-effective treatments for the management of HCV infection in Africa
- Pre-, on-, and post-treatment assessments during HCV management

The recommendations for the use of optimal treatment regimens in the management of HCV infection were graded by the expert panel as Preferred, Alternative, or Not Recommended (Table 1).

| Grading of the recommendation | Definition of the grading |
|-----------------------------|---------------------------|
| Preferred                   | Treatment can be used in most patients and recommendation is based on optimal efficacy, favorable tolerability and toxicity profiles, duration, and pill burden. |
| Alternative                 | Treatment can be the one that is effective but with potential disadvantages/limitations for use in certain patient populations or with less supporting data as compared with the recommended regimens. In certain situations, an alternative regimen may be an optimal regimen for a specific patient situation. |
| Not recommended             | Treatment is clearly inferior compared with the recommended or alternative regimens because of factors such as lower efficacy, unfavorable tolerability and toxicity, longer duration, and/or higher pill burden. Unless otherwise indicated, such regimens should not be administered to patients with HCV infection. |

### Diagnosis of HCV infection

Initial HCV serological testing is recommended by several current guidelines for the detection of anti-HCV antibodies.21–23 The chronic nature of the infection may be further confirmed by a sensitive nucleic acid diagnostic assay for the detection of HCV RNA.24 The use of a qualitative HCV RNA assay may be considered as a feasible option for providing broader access to HCV diagnosis and care in low- and middle-income countries, especially if pan-genotypic therapies are available (Box 1). Quantification of HCV core antigen, a surrogate marker of HCV replication, may also be used instead of the HCV RNA test for the diagnosis of HCV infection. The lower sensitivity of the core antigen test (lower limit of detection 3 log_{10} IU/mL) makes this test less useful in detecting early infection or HCV clearance. However, the HCV core antigen test is suitable for confirming established chronic HCV infection and for determining sustained virological response or cure post-treatment. An initial negative HCV serological test result does not indicate the absence of HCV infection; negative test result may be possible in cases of acute infection, in immunocompromised patients, or in patients on dialysis. In these patients, HCV RNA testing may be considered as part of the initial assessment for the diagnosis of HCV infection.25

The severity of liver disease is a key factor in planning initial treatment and further follow-up evaluation of patients.26–28 Patients with confirmed HCV infection should be evaluated to assess the degree of liver fibrosis and cirrhosis by liver biopsy or other non-invasive tests.29 The utility of liver biopsy is limited by the cost, invasiveness,
and the risk of complications. Non-invasive tests have replaced liver biopsy to estimate the extent of liver disease in patients with chronic viral hepatitis in most countries. The most widely used noninvasive test is transient elastography (Fibroscan®), but availability and cost constraints may limit the use of elastography in resource-limited settings. In case of unavailability of transient elastography, the AST-to-platelet ratio index (APRI) or fibrosis-4 (FIB-4) index score may be useful in liver fibrosis assessment. Additionally, testing for HCV genotype is recommended before treatment initiation to tailor the treatment strategy to suit the patient. It is pertinent to mention here, that the use of pan-genotypic treatment regimens such as velpatasvir-based regimens obviates the need for HCV genotype testing prior to initiating treatment (Box 1). Hence, pan-genotypic regimens significantly reduce the total cost of diagnosis of HCV infection, which is an added advantage in developing countries.

**Consensus recommendations for the diagnosis of HCV infection**

i. Anti-HCV testing is recommended for screening/initial testing, and if the result is positive, current infection should be confirmed by a sensitive HCV RNA/core antigen testing.

ii. Qualitative HCV RNA testing is a reasonable, good, and cost-effective method, and can replace quantitative testing.

iii. Genotyping is recommended to guide selection of the most suitable antiviral regimen.

iv. A pan-genotypic regimen such as sofosbuvir-velpatasvir therapy may obviate the need for genotyping.

**Screening of HCV infection**

Serological testing for HCV may be offered to high-risk individuals, and those with a history of HCV risk exposure or behavior such as the following: (1) individuals who have undergone medical or dental interventions in settings with inappropriate infection-control practices; (2) individuals who have received blood transfusions without HCV serological testing of the donated blood; (3) patients on hemodialysis; (4) people who inject drugs (annual testing is recommended); (5) individuals who have had tattoos, body piercing, or scarification procedures done with inappropriate infection-control practices; (6) children born to mothers infected with HCV; (7) individuals with human immunodeficiency virus (HIV) infection (annual testing is recommended); (8) individuals who use/have used intranasal illicit drugs; (9) commercial sex workers; (10) prisoners (HIV) infection (annual testing is recommended); (11) women who have undergone genital excision; (12) men with a history of non-medical circumcision; and (13) patients with liver disease from any cause.

Rapid ‘point-of-care’ (POC) anti-HCV antibody diagnostic tests employing serum, plasma, fingerstick whole blood, or saliva may be used as alternatives to standard enzyme immunoassays as a part of the screening programs. Rapid POC HCV RNA tests are available in Africa such as Cepheid GenXpert®, where these are already in use as POC TB and HIV diagnostic tests.

**Treatment of HCV infection**

The main aim of HCV treatment should be to attain sustained virologic response (SVR). Further, the subsequent reduction in all cause-mortality and prevention of liver-associated adverse effects, end-stage liver disease, hepatocellular carcinoma (HCC), and severe extrahepatic manifestations should also be a part of the treatment goals for the management of HCV infection.

**Pre-treatment assessments**

Selection of treatment for the management of HCV infection may be optimized by assessing the liver disease severity and virologic parameters before starting the treatment. Other factors that should be assessed include alcoholism, co-infection with hepatitis B virus or HIV, renal impairment, diabetes mellitus, autoimmune, and cardiac diseases.

Patients with hepatitis B virus (HBV)-HCV co-infection have been noted to have accelerated progression of liver disease and an increased risk of HCC. Furthermore, HBV reactivation has been found to occur during treatment of HCV infection with DAAs in these individuals. However, HBV reactivation may be rare among patients with resolved HBV infection. Therefore, the expert panel recommended that all HCV patients should be tested for hepatitis B surface antigen (HBsAg) prior to initiating HCV DAA treatment, and all HBV-HCV co-infected patients who test positive for HBsAg, particularly those with quantifiable HBV DNA (increase in HBV DNA by at least 1 log and elevation in alanine transaminase [ALT] >Upper limit of normal [ULN]) should be initiated on HBV antiviral treatment (Box 2).

Patients with HCV infection, especially those with cirrhosis, are at a higher risk of developing HCC. Hence, HCC surveillance through simple and cost-effective alpha-fetoprotein (AFP) test is recommended in addition to liver ultrasound (Box 2). Furthermore, assessment of HCV RNA or HCV core antigen before initiation of treatment, staging of cirrhosis or fibrosis and assessment of potential drug-drug interactions are also important. Transient elastography, and/or non-invasive serum markers may be used to assess advanced liver fibrosis. Genotype assessment is recommended to individualize the treatment dose and duration which will further help optimize the treatment outcomes. However, as discussed above, with the use of pan-genotypic treatment regimens (such as velpatasvir-based regimens), the need for HCV genotype testing is obviated.

**Consensus recommendations on pre-treatment assessments**

i. Liver fibrosis assessment: The use of transient elastography or non-invasive serum markers is recommended for deciding on the regimen and the need for initiating additional measures for the management of cirrhosis (e.g., HCC screening)

ii. Assessment for potential drug-drug interactions with concomitant medications

iii. The following laboratory tests are recommended:

   a. Complete blood count (CBC)
   b. Hepatic function tests (albumin, total and direct bilirubin, ALT, aspartate aminotransferase [AST], and alkaline phosphatase levels)
   c. Calculated glomerular filtration rate (GFR)
   d. HBsAg
   e. HIV testing
   f. AFP in patients with cirrhosis

**Citation:** Gane EJ, Charlton MR, Onyekwere CA, et al. Consensus recommendations on the diagnosis and treatment of hepatitis c virus infection in sub Saharan Africa. *Gastroenterol Hepatol Open Access.* 2019;10(4):181–193. DOI: 10.15406/ghoa.2019.10.00380
Who should be treated?

All patients with chronic HCV infection should be considered for treatment, except those with limited lifespan, in whom HCV eradication will provide no benefit. Patients with decompensated cirrhosis should be referred to a tertiary care center and managed by experts with relevant clinical experience. Additionally, factors influencing the decision to treat are: the age of the patient, occupations with a high risk of transmission to others, impact on quality of life, co-morbidities and the potential for the occurrence of serious side effects.21,24

Direct-acting antiviral agents available in Africa

Ribavirin and pegylated interferon (Peg-IFN) were the preferred treatment regimens for HCV infection before the advent of DAAs. The agents used earlier were inconvenient, with the need to administer injections for up to one year, and had an unpleasant adverse-effect profile, along with low cure rates; the resulting treatment uptake was very poor (<1% in most countries). The management of chronic HCV has noticeably improved with the introduction of DAAs. Currently, three classes of DAAs are in use: second-generation NS3/4A serine protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors. Drugs from two of these specified classes are used as various combination regimens for the management of HCV in the African region.14 The DAA regimens available in various African countries, along with their key pharmacological properties, were summarized by the expert panel, as shown in Table 2.25,36,37,38 The DAA regimens are also used in combination with ribavirin, which is a nucleoside analog available as a 200 mg tablet. The dose of ribavirin is dependent on the patient’s body weight and HCV genotype. Dose reduction or discontinuation of ribavirin is recommended in patients who experience adverse reactions or renal impairment.39

Treatment of patients with HCV GT1 infection

Four regimens have been proposed for the treatment of patients with chronic HCV GT1 infection (Table 3).

Table 2 Direct-acting antiviral treatment regimens: Availability in specific African countries and key pharmacological properties

| Country          | DAA regimens | Mode of action | Dose | Cmax | Major elimination route | Drug interactions |
|------------------|--------------|----------------|------|------|-------------------------|-------------------|
|                  | SOF          | LDV/SOF        | DCV  | VEL  | Renal                   | P-gp inducers, CYP|
|                  |              |                |      |      | Biliary                 | enzyme inhibitors |
|                  |              |                |      |      | Faeces                  | amiodarone        |
|                  |              |                |      |      | VEL: 3h                 |                   |
| Ivory Coast      | ✓            | ✓              | ✓    | ✓    | 0.5–2h                  |                   |
| Cameroon         | ✓            | ✓              | ✓    | ✓    | LDV: 4–4.5h             |                   |
| Burkina Faso     | ✓            | ✓              | ✓    | ✓    | 2h                      |                   |
| Senegal          | ✓            | ✓              | ✓    | ✓    | LDV: Biliary            |                   |
| Zimbabwe         | ✓            | ✓              | ✓    | ✓    | Faeces                  |                   |
| Namibia          | ✓            | ✓              | ✓    | ✓    | VEL: Biliary            |                   |
| Nigeria          | ✓            | ✓              | ✓    | ✓    | None                    |                   |
| Ghana            | ✓            | ✓              | ✓    | ✓    | None                    |                   |
|                  |              |                |      |      |                         |                   |

1 Available through import permit; 2 Available under special access; 3 Orally, once-daily, without regard to food; 4 eGFR <30 ml/min/1.73 m²; 5 Examples include rifampin and St John’s wort.

DCV, Daclatasvir; LDV, ledipasvir; SOF, sofosbuvir; VEL, velpatasvir; Cmax, peak plasma concentration; eGFR, Estimated glomerular filtration rate; P-gp, P-glycoprotein; CYP, Cytochrome P450; HCV, hepatitis C virus; RNA, ribonucleic acid

Citation: Gane EJ, Charlton MR, Onyekwere CA, et al. Consensus recommendations on the diagnosis and treatment of hepatitis c virus infection in sub-Saharan Africa. Gastroenterol Hepatol Open Access. 2019;10(4):181–193. DOI: 10.15406/ghoa.2019.10.00380
Table 3 Recommended treatment regimens for HCV GT1 infection

| Recommendation category | Treatment option/s | Treatment regimens |
|-------------------------|-------------------|--------------------|
| i. SOF+VEL ±RBV*          | i. SOF+VEL for 12weeks (Addition of RBV may be considered in difficult-to-treat [treatment-experienced, cirrhotic] patients) |
| ii. In patients with decompensated cirrhosis (currently treated hepatic encephalopathy or ascites or Child-Pugh-Turcotte class B or C): SOF+VEL+weight-based RBV for 12weeks |
| iii. LDV+SOF for 12weeks | iii. LDV+SOF for 12weeks |
| iv. In treatment-naive patients with HCV RNA <6 million IU/mL in whom cirrhosis has been conclusively ruled out by transient elastography (Fibroscan) or biopsy: LDV+SOF for 8 weeks |
| v. In treatment-experienced cirrhotic patients/patients with decompensated liver disease/post-liver transplant patients: LDV+SOF+RBV for 12 weeks OR LDV+SOF for 24 weeks if RBV is ineligible |
| vi. SOF+DCV for 12 weeks (Addition of RBV may be considered if cirrhosis has not been conclusively ruled out) |
| vii. In patients with compensated cirrhosis: SOF+DCV ± weight-based RBV for 24 weeks |
| viii. In patients with decompensated cirrhosis: SOF+DCV+RBV for 12 weeks (OR) SOF+DCV for 24 weeks if RBV is ineligible |

DCV, Daclatasvir; GT, genotype; HCV, Hepatitis C virus; LDV, Ledipasvir; RBV, Ribavirin; RNA, Ribonucleic acid; SOF, sofosbuvir; VEL, Velpatasvir.

*RBV to be dosed as per body weight.

**Sofosbuvir + velpatasvir ± ribavirin**

The findings from the phase III, double-blind, placebo-controlled, randomized ASTRAL-1 trial formed the foundation for the use of sofosbuvir plus velpatasvir regimen for the treatment of patients with HCV GT1 infection. This study enrolled treatment-naive and previously treated patients with HCV GT1, GT2, GT4, GT5, or GT6 infections, including those with compensated cirrhosis. The enrolled patients were randomized (in a 5:1 ratio) to receive either velpatasvir or sofosbuvir combination (n=624), or placebo (n=116). Treatment with the velpatasvir and sofosbuvir combination for 12 weeks resulted in an overall 99% SVR (98% and 99% SVR in GT1a and GT1b patients, respectively). The safety of the combination was comparable to placebo.42 The ASTRAL-4 is another phase III, open-label study that was conducted among treatment-naive and -experienced HCV patients with GT1 through GT6 infections (n=267; GT1: 78%) and decompensated cirrhosis. Patients received sofosbuvir and velpatasvir for 24 weeks (n=90), or sofosbuvir and velpatasvir once daily with (n=87) or without (n=90) ribavirin for 12 weeks. The corresponding SVR rates in GT1a-infected patients were 93%, 94%, and 88%, respectively, and in GT1b-infected patients 88%, 100%, and 89%, respectively.44 ASTRAL-5 was another phase III, single-arm study in HCV GT1 through GT6 patients with HIV-1 co-infection, including those with compensated cirrhosis. In this study, sofosbuvir and velpatasvir regimen given for 12 weeks was found to be safe and resulted in a 95% SVR in GT1 patients.45 Furthermore, a review of 23 randomized clinical trials concluded sofosbuvir + velpatasvir with/without ribavirin regimen, to be effective for the treatment of patients with HCV across GT 1 to 6 infections.45 In HCV patients on 12 or 24 weeks sofosbuvir/velpatasvir with/without ribavirin, the ribavirin-free regimen was found to be associated with improved patient-reported outcomes.44

**Sofosbuvir + ledipasvir ± ribavirin**

The phase III ION-1 trial evaluated a regimen of sofosbuvir and ledipasvir (taken for 12 or 24 weeks) in treatment-naive patients with chronic HCV GT1 infection (n=865; 16% with cirrhosis). The study findings revealed that the regimen was highly effective with a 97%-99% SVR.44 In the ION-3 trial, a combination of sofosbuvir and ledipasvir for a duration of 8 weeks resulted in high SVR rates of 94% in previously untreated patients with HCV GT1 infection without cirrhosis. The SVR rates with the 8-week regimen were comparable with the 12-week sofosbuvir and ledipasvir combination regimen or the 8-week sofosbuvir and ledipasvir combination regimen with ribavirin. Furthermore, the sofosbuvir and ledipasvir combination was found to be safe and tolerable.44 A retrospective analysis of 100 chronic HCV patients from the ION-1 trial who achieved SVR at 12 weeks post-treatment with sofosbuvir/ledipasvir with or without ribavirin revealed that the ribavirin-free regimen was associated with reduced fatigue-related patient-reported outcomes.45 In a separate open label, single center study conducted among HCV GT1 or 4 patients who were receiving treatment for sickle cell disease, sofosbuvir and ledipasvir...
combination for 12- or 24-weeks duration was found to be safe. A recent prospective study (SHARED trial) evaluated the combination of sofosbuvir and ledipasvir in GT1/4 HCV patients and found an 86.7% SVR rate with the 12-week regimen. Additionally, the study showed the combination to be safe with an adherence rate >98%. Recent findings from another international, non-randomized pilot study in GT1, 2 and 4 treatment-naive HCV patients revealed 100% adherence to the sofosbuvir and ledipasvir combination and reported an SVR of 90% for GT1 HCV subtype patients. The combination was also found to be safe and effective in HIV co-infected patients. TheION-4 multicentric open label trial reported an SVR rate of >95% in treatment-naïve and experienced patients with HCV GT1 infection co-infected with HIV-1.

Sofosbuvir + velpatasvir ± ribavirin

The regimen in focus was evaluated in treatment-naïve patients with HCV GT1 through GT3 infection for a duration of 24 weeks and in treatment-experienced patients with GT1 infection for 12 or 24 weeks in the open-label, A1444040 trial. The SVR rate was 98%, both in treatment-naive and -experienced patients with GT1 infection. The open-label, phase III ALLY-1 trial enrolled patients with HCV of all genotypes. Treatment of the enrolled patients with daclatasvir plus sofosbuvir with ribavirin for 12 or 24 weeks in this trial was safe and exhibited an SVR rate of 82% in GT1 patients with cirrhosis and 95% in GT1 transplant recipients. The 24-weeks duration regimen of this combination was found to be safe and effective in recurrence of HCV GT1 cases, post liver transplantation, including those with HIV-1 co-infection or with decompensated cirrhosis. Studies conducted in real-world settings also support the efficacy and safety of this regimen for HCV GT1 infection in diverse population with severe liver disease.

Treatment of Patients with HCV GT2 Infection

Four regimens were proposed by the panel for the treatment of patients with chronic HCV GT2 infection (Table 4).

Sofosbuvir + velpatasvir ± ribavirin

In the randomized, phase III, open-label ASTRAL 2 trial, treatment-naïve and -experienced patients with GT2 infection, including those with compensated cirrhosis, were randomized to receive once-daily sofosbuvir and velpatasvir (n=134) or sofosbuvir plus weight-based ribavirin (n=132) for 12 weeks. The corresponding SVR rates were 99% and 94%, respectively. The SVR rate with this 12-week combination regimen without ribavirin was 100% in GT2-infected patients in the ASTRAL 1 trial. The ASTRAL 4 study enrolled patients with decompensated cirrhosis and reported that the SVR rate was 100% in GT2-infected patients treated with this combination, with or without ribavirin, for 12 weeks. Furthermore, while comparing patient reported outcomes (PROs) for the HCV patients with GT2 infection (ASTRAL 2 and 3) it was found that patients receiving the ribavirin-free regimen reported significantly better PRO scores during treatment compared with those receiving the RBV-containing regimen. Results from another recent international, non-randomized pilot study conducted among GT1, 2 or 4 treatment-naive HCV patients revealed 94% adherence to the sofosbuvir plus velpatasvir combination and reported an SVR of 90% for the GT2 HCV subtype of patients. The combination was also found to be safe and effective in HIV co-infected patients.

Sofosbuvir + ledipasvir ± ribavirin

In a phase III, randomized, open-label trial, the efficacy and safety of sofosbuvir and ledipasvir were assessed for the treatment of HCV GT2-infected patients with cirrhosis and/or prior treatment failure. Two cohorts of patients were considered for the study. Cohort 1 with ribavirin-tolerant eligible patients was randomized in a 1:1 ratio to receive ledipasvir plus sofosbuvir (n=106) or sofosbuvir plus ribavirin (n=108), both for 12 weeks. Cohort 2 with patients not eligible for or intolerant to ribavirin treatment was treated with 12 weeks of ledipasvir plus sofosbuvir therapy (n=25). The primary endpoint of SVR12 was achieved by 96% of patients treated with ledipasvir plus sofosbuvir, both in cohorts 1 and 2. The treatment was well-tolerated, and no treatment-emergent resistance was noted.

Sofosbuvir + daclatasvir ± ribavirin

This regimen given for 24 weeks was associated with an SVR of 92% in treatment-naive HCV GT2-infected patients without cirrhosis in the A1444040 trial. Furthermore, daclatasvir plus sofosbuvir with ribavirin for 12 or 24 weeks was found to be safe and exhibited an 80% SVR rate in GT2-infected patients with cirrhosis in the ALLY-1 trial. In the ALLY-2 trial, in HCV patients co-infected with HIV-1, the overall SVR rates across GT1 through GT4 in treatment-naïve and -experienced patients treated with the 12-week daclatasvir plus sofosbuvir regimen were noted to be 97% and 98%, respectively.

Sofosbuvir + ribavirin

In an international, one-arm, non-randomized study to evaluate the efficacy of a 12-week regimen of sofosbuvir and weight-based ribavirin for the treatment of treatment-naïve HCV GT 2-infected patients in West and Central Africa, an SVR rate of 90% was achieved with the combination. Sofosbuvir plus ribavirin for 12 weeks was associated with a 97% SVR in treatment-naive patients with GT2 infection, including in those with cirrhosis in the FISSION trial. Furthermore, this regimen was found to be effective in both treatment-naïve and treatment-experienced HCV GT2-infected patients co-infected with HIV-1 in the PHOTON 1 and 2 trials (SVR: 88% and 92%, respectively, in PHOTON 1; SVR: 89% and 83%, respectively, in PHOTON 2).

Treatment of Patients With HCV GT3 Infection

The preferred and alternative regimens for the treatment of HCV GT3 infection are given in Table 5.
Table 4 Recommended treatment regimens for HCV GT2 infection

| Recommendation category | Treatment option(s) | Treatment regimen |
|-------------------------|---------------------|-------------------|
| Preferred               | SOF+VEL ± RBV
                           | i. SOF+VEL for 12 weeks (Addition of weight-based RBV may be considered for decompensated cirrhosis) |
|                         | LDV+SOF ± RBV
                           | ii. LDV+SOF for 12 weeks (Addition of RBV may be considered based on the physician's discretion in treating difficult-to-treat patients [treatment-experienced patients, patients with cirrhosis]) |
|                         | iii. In case of previous SOF treatment failure: LDV+SOF+RBV for 12 weeks |
|                         | SOF+DCV ± RBV
                           | iv. SOF+DCV for 12 weeks |
|                         | v. In decompensated cirrhosis: SOF+DCV+RBV for 12 weeks |
|                         | SOF+RBV
                           | vi. SOF+RBV for 12 weeks (Data are not available for patients with decompensated cirrhosis) |

DCV, Daclatasvir; HCV, Hepatitis C virus; GT, Genotype; RBV, Ribavirin; SOF, Sofosbuvir; VEL, Velpatasvir; LDV, Ledipasvir.

#RBV to be dosed as per body weight

Table 5 Recommended treatment regimens for HCV GT3 infection

| Recommendation category | Treatment option(s) | Treatment regimen |
|-------------------------|---------------------|-------------------|
| Preferred               | SOF+VEL ± RBV
                           | i. SOF+VEL for 12 weeks (Addition of RBV may be considered based on the physician's discretion in treating difficult-to-treat patients [treatment-experienced patients, patients with cirrhosis]) |
|                         | ii. SOF+VEL for 12 weeks (Addition of weight-based RBV may be considered for decompensated cirrhosis) |
|                         | iii. SOF+DCV for 12 weeks (Addition of RBV may be considered if cirrhosis has not been conclusively ruled out) |
|                         | iv. In patients with compensated cirrhosis |
|                         | v. Treatment-naive patients: SOF+DCV+RBV for 12 weeks |
|                         | vi. Treatment-experienced patients: SOF+DCV+RBV for 24 weeks |
|                         | vii. In patients with decompensated cirrhosis |
|                         | viii. SOF+DCV+RBV for 12 weeks |
|                         | ix. If RBV ineligible: SOF+DCV for 24 weeks |
|                         | x. SOF+RBV for 24 weeks (should be considered only when preferred regimens are not available) |
|                         | xi. LDV+SOF+RBV for 12 weeks (should be considered only when preferred regimens are not available) |

DCV, Daclatasvir; GT, Genotype; HCV, Hepatitis C virus; LDV, Ledipasvir; RBV, Ribavirin; SOF, Sofosbuvir; VEL, Velpatasvir.

#RBV to be dosed as per body weight
Consensus recommendations on the diagnosis and treatment of hepatitis C virus infection in sub-Saharan Africa

60

56

50

78

40

41

62,63

51

59

40x47

Saharan Africa.

Citation: Gane EJ, Charlton MR, Onyekwere CA, et al. Consensus recommendations on the diagnosis and treatment of hepatitis C virus infection in sub-Saharan Africa. Gastroenterol Hepatol Open Access. 2019;10(4):181–193. DOI: 10.15406/ghoa.2019.10.00380

Sofosbuvir + velpatasvir ± ribavirin

The combination regimen of sofosbuvir and velpatasvir for 12 weeks was found to be effective with 93% SVR rates in HCV GT3-infected patients in the ASTRAL-3 trial. The SVR rate in treatment-naïve and treatment-experienced patients were 97%, and 90%, respectively. The SVR rate in patients with cirrhosis was 91%, and in patients without cirrhosis was 97%.60 The ASTRAL-4 study enrolled treatment-naïve and treatment-experienced patients with decompensated cirrhosis. In this study, the SVR rate with sofosbuvir and velpatasvir plus ribavirin for 12 weeks was 85% conducted among GT3-infected patients.61 In another retrospective analysis conducted in HCV-infected patients with GT1 through GT6 infections, the SVR rate after 12 weeks of treatment with sofosbuvir and velpatasvir regimen in patients with GT3 infection was found to be 95% and none of the patients in the analysis discontinued the treatment due to adverse events. Also, the combination was found to be effective in patients with advanced fibrosis and cirrhosis.62 Furthermore, sofosbuvir and velpatasvir once daily for 12 weeks has been found to be effective with a 92% SVR rate in HCV GT3-infected patients co-infected with HIV-1.63 A recent meta-analysis conducted among 2975 patients with HCV GT2 and 3 infections showed sofosbuvir combination with velpatasvir (with or without ribavirin) regimen to have a higher SVR rate at 12 weeks after the treatment with a lower adverse events rate compared to sofosbuvir combined with ribavirin (with or without peg-IFN) regimen (94.9% versus 80.7%).64

Sofosbuvir + daclatasvir ± ribavirin

The SVR rate with this regimen given for 24 weeks was 89% in treatment-naïve HCV GT3-infected patients without cirrhosis in the phase II AI444040 trial.65 In the ALLY-3 trial, the SVR rate with the 12-week regimen of daclatasvir plus sofosbuvir in treatment-naïve GT3-infected patients was 90%, and in treatment-experienced patients, the SVR rate was 86%.66 In the ALLY-3 trial, the safety and efficacy of a 12- or 16-week regimen of daclatasvir plus sofosbuvir and ribavirin was assessed in both treatment-naïve and treatment-experienced GT3-infected patients with advanced fibrosis or compensated cirrhosis. The overall SVR was 90%. The SVR rate in the 12-week subgroup was 88%, and 83% in the 12-week subgroup with cirrhosis.67 Furthermore, daclatasvir plus sofosbuvir with ribavirin for 12 or 24 weeks exhibited an 83% SVR rate in GT3-infected patients with cirrhosis and a 91% SVR rate in GT3-infected transplant recipients in the ALLY-1 trial.68 In HCV-HIV-1 co-infected patients, the overall SVR rates across GT1 through GT4 with a 12-week regimen of daclatasvir plus sofosbuvir were noted to be 97% and 98%, in treatment-naïve and treatment-experienced patients, respectively in the ALLY-2 trial.69,70 In one of the early access programs, daclatasvir combined with sofosbuvir, with/without ribavirin, was found to be effective in patients with life-threatening disease and high unmet needs as it provided high SVR12 rates with a good safety profile.69 In real-world settings (in the European and French compassionate programs), daclatasvir combined with sofosbuvir, with/without ribavirin has been found to be effective as well as well-tolerated in HCV GT3-infected patients, including those with prior treatment experience or with cirrhosis.71-74

Sofosbuvir + ribavirin

The regimen of sofosbuvir and ribavirin has been found to be effective in both treatment-naïve and treatment-experienced HCV GT3-infected patients co-infected with HIV; the overall SVR has been reported to be 89% after 12 weeks of treatment with the combination.66

Sofosbuvir + ledipasvir + ribavirin

In a phase 2, open-label trial in patients with HCV GT3 or GT6 infection, this regimen given for 12 weeks was associated with 100% SVR rate in GT3-infected patients.75 Another open-label trial revealed an overall 89% SVR with the regimen in HCV GT3-infected patients.76

Treatment of patients with HCV GT4 infection

Four treatment options have been proposed by the expert panel for the treatment of patients with HCV GT4 infection (Table 6).

Sofosbuvir + velpatasvir ± ribavirin

Once-daily sofosbuvir and velpatasvir combination given for 12 weeks was associated with 100% SVR in GT4-infected patients in the phase III ASTRAL-1 trial. This study included both treatment-naïve and treatment-experienced patients, including those with compensated cirrhosis.77 In the ASTRAL-4 study, which included patients with decompensated cirrhosis, sofosbuvir and velpatasvir combination for 24 weeks or for 12 weeks with or without ribavirin yielded a 100% SVR in GT4-infected patients.78 Sofosbuvir and velpatasvir combination for 12 weeks was found to be safe and was also associated with a 100% SVR in GT4-infected patients co-infected with HIV-1.79

Sofosbuvir + ledipasvir + ribavirin

Sofosbuvir and ledipasvir combination for 12 weeks resulted in a 100% SVR rate in treatment-naïve and treatment-experienced HCV GT4-infected patients, including those with cirrhosis in the National Institute of Allergy and Infectious Diseases (NIAID) SYNERGY trial.80 High SVR rates were also noted with this regimen in other phase 2 studies in involving similar patient cohorts.81 Real-world studies also support the efficacy of this combination regimen with high SVR rates (95.4%) in GT4-infected patients, including those with cirrhosis (SVR: 93.2%).82 In the SOLAR-2 study, sofosbuvir, ledipasvir, and ribavirin combination for 12 and 24 weeks was associated with 78% and 94% SVR, respectively, in HCV GT4-infected patients with advanced liver disease.83 Furthermore, in the ION-4 trial, use of the sofosbuvir and ledipasvir fixed-dose combination for 12 weeks was associated with 100% SVR in GT4-infected patients co-infected with HIV-1.84 This study enrolled both treatment-naïve and treatment-experienced patients, including those with cirrhosis.85 Results from an international, non-randomized pilot study in GT4 treatment-naïve HCV patients revealed a 100% adherence to the sofosbuvir and ledipasvir combination and reported an SVR of 87.2% for the GT4 HCV subtype patients. The combination was also found to be safe and effective in HIV co-infected patients.86 Furthermore, the SHARED trial which evaluated the combination of sofosbuvir and ledipasvir in GT1/4 HCV patients, found an 86.7% SVR rate with the 12-week regimen. Additionally, the study showed the combination to be safe and the adherence rate to be >98%.87

Sofosbuvir + daclatasvir ± ribavirin

The combination of daclatasvir and sofosbuvir with ribavirin given for 12 or 24 weeks was associated with a 100% SVR in GT4-infected patients with cirrhosis in the ALLY-1 trial.69 In the ALLY-2 trial, daclatasvir plus sofosbuvir given for 12 weeks was found to be effective in treating GT1 through GT4 HCV patients co-infected with HIV-1, with 100% SVR in GT4-infected patients.88,89

Citation: Gane EJ, Charlton MR, Onyekwere CA, et al. Consensus recommendations on the diagnosis and treatment of hepatitis C virus infection in sub-Saharan Africa. Gastroenterol Hepatol Open Access. 2019;10(4):181–193. DOI: 10.15406/ghoa.2019.10.00380
### Table 6 Recommended treatment regimens for HCV GT4 infection

| Recommendation category | Treatment option(s) | Treatment regimen |
|-------------------------|---------------------|-------------------|
| **Preferred**           | SOF+VEL ± RBV       | i. SOF+VEL for 12 weeks (Addition of RBV may be considered based on the physician’s discretion in treating difficult-to-treat patients [treatment-experienced patients, patients with cirrhosis])  
ii. In patients with decompensated cirrhosis: SOF+VEL+weight-based RBV for 12 weeks |
|                         | SOF+DCV ± RBV       | v. SOF+DCV for 12 weeks (Addition of RBV may be considered if cirrhosis has not been conclusively ruled out)  
vii. If RBV is ineligible, SOF+DCV for 24 weeks |
| **Alternatives**        | SOF+DCV ± RBV       | vi. Cirrhosis of any class: SOF+DCV+RBV for 12 weeks |

DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.

#RBV to be dosed as per body weight

### Treatment of patients with HCV GT5 or GT6 infections

The preferred and alternative regimens for the treatment of HCV GT5 or GT6 infections are given in Table 7.

**Sofosbuvir + velpatasvir ± ribavirin**

In the ASTRAL-1 study, treatment with once-daily sofosbuvir and velpatasvir for 12 weeks was associated with 97% and 100% SVR rates in patients with GT5 and GT6 infections, respectively. In a separate phase 2 study, the SVR rate with this combination was 95%-96% for GT5- and GT6-infected patients. Furthermore, treatment with sofosbuvir and velpatasvir for 24 weeks in patients with GT6 infection was associated with 100% SVR rate in the ASTRAL-4 study.

**Sofosbuvir + ledipasvir ± ribavirin**

Treatment with the sofosbuvir and ledipasvir regimen for 12 weeks in GT5-infected treatment-naive and treatment-experienced patients, including those with cirrhosis, has been found to be safe and associated with a 95% SVR rate. In a separate study, in patients with GT3 or GT6 infection, treatment-naive and treatment-experienced patients with GT6 infection (n=25) treated with the combination for 12 weeks attained a 96% SVR rate.

**Sofosbuvir + daclatasvir ± ribavirin**

The ALLY-1 trial evaluated sofosbuvir, daclatasvir, and ribavirin combination across all genotypes in HCV patients with advanced liver disease. Sustained virologic response was achieved in one GT6-infected liver transplant recipient treated with the combination.

### Treatment of patients in situations where GT testing is not available

The pan-genotypic velpatasvir regimens recommended by the Expert Panel for the treatment of HCV-infected patients in situations where GT testing is not available, include: (1) sofosbuvir plus velpatasvir for 12 weeks in treatment-naive noncirrhotic patients; (2) sofosbuvir plus velpatasvir with/without ribavirin for 12 weeks in treatment (Peg-IFN)-experienced noncirrhotic patients; (3) sofosbuvir plus velpatasvir for 12 weeks in treatment-naive cirrhotic patients; (4) sofosbuvir plus velpatasvir with/without ribavirin for 12 weeks in treatment (Peg-IFN)-experienced cirrhotic patients; and (5) sofosbuvir plus velpatasvir with ribavirin for 12 weeks in decompensated cirrhotic patients.
**Table 7.** Recommended treatment regimens for HCV GT5 or GT6 infections

| Recommendation category | Treatment option(s) | Treatment regimen |
|-------------------------|--------------------|-------------------|
| **Preferred**            | 1. SOF+VEL ± RBV#   | SOF+VEL for 12 weeks (Addition of RBV may be considered based on the physician’s discretion in treating difficult-to-treat patients [treatment-experienced patients, patients with cirrhosis].) |
|                         | i. In patients with decompensated cirrhosis: SOF+VEL+weight-based RBV for 12weeks |
|                         | 2. LDV+SOF ± RBV#   | LDV+SOF for 12 weeks (Addition of RBV may be considered based on the physician’s discretion in treating difficult-to-treat patients [treatment-experienced patients, patients with cirrhosis].) |
|                         | ii. In case of previous SOF treatment failure: LDV+SOF+RBV for 12weeks |
| **Alternatives**         | SOF+DCV ± RBV#      | SOF+DCV for 12weeks (Addition of RBV may be considered if cirrhosis has not been conclusively ruled out) |
|                         | iii. Cirrhosis of any class: SOF+DCV+RBV for 12weeks |
|                         | iv. If RBV is ineligible, SOF+DCV for 24weeks |

DCV, daclatasvir; HCV, hepatitis C virus; GT, genotype; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.

#RBV to be dosed as per body weight

**On- and post-treatment assessments**

Assessing the on-treatment efficacy and safety, monitoring drug-drug interactions, and evaluating medication adherence are crucial for achieving better treatment outcomes during the management of HCV infection. Conducting optimal follow-up and assessments post-treatment helps establish the successful elimination of the virus and prevents relapses. The on- and post-treatment assessments recommended by the expert panel are listed in Table 8.

**Table 8.** On- and post-treatment assessments during the management of HCV infection

| Assessments | Expert recommendations |
|-------------|------------------------|
|             | i. In patients with cirrhosis, CBC, creatinine level, calculated GFR, and hepatic function panel may be repeated after 4 weeks. |
| On-treatment| ii. All patients on RBV should have CBC done at 4 and 8 weeks to monitor for hemolysis. |
|             | iii. HCV RNA testing (qualitative/quantitative) is not required, as there are no current recommendations for response-guided therapy. Testing may be done at the end of treatment, but it is not mandatory. |
|             | iv. Assessment of potential drug-drug interactions with concomitant medications is recommended. |
|             | v. Periodic reviews of therapy compliance and the general condition of the patient are recommended. |
Summary and future directives

One of the major unmet needs in Africa is the need for developing structured region-specific guidelines on the diagnosis and treatment of HCV infection that can help guide clinical practice decisions. The current African consensus document aims to provide necessary guidance to the clinicians practicing in the region for the cost-effective and optimal management of HCV infection. The document encapsulates the key recommendations from the expert panel on the diagnosis, screening, and treatment of HCV infection along with summarizing, the pre-, on-, and post-treatment assessment of patients with HCV infection in Africa. In addition to translating these evidence-based recommendations to clinical practice, it is imperative that physicians in this region individualize and optimize the management of HCV infection and contribute to enhancing the patients’ awareness of the disease. Improving access to newer and safer treatments may also help in further optimization of treatment outcomes in resource-limited settings such as Africa.

Acknowledgements

We would like to thank Mylan Pharmaceuticals Ltd for financial support in execution of this project. We would also like to thank BioQuest Solutions Ltd for providing writing assistance.

Conflicts of interests

Author Edward John Gane: Member of Clinical Advisory Board for Gilead Sciences, AbbVie, Janssen, Arrowhead, Merck, VJR Biotechnology, and Assembly Bio. Member of Speakers’ Bureau for Gilead Sciences, AbbVie, Mylan Pharmaceuticals

Author Michael Charlton: Consulting and research support for Gilead Sciences, Merck, AbbVie, Novartis and Only consulting support for Mylan

Author Nadia Jacqueline Mandeng: Transport and accommodation in the consensus building meetings was provided by Mylan

Author Ravishankar AC: Employee of Mylan Pharmaceuticals Private Limited

Author Sanjay Hadigal: Employee of Mylan Pharmaceuticals Private Limited

Funding information

The project is supported by Mylan Pharmaceuticals Ltd.

References

1. ICTV master species list 2016 (MSL31) v1.3.
2. Hepatitis C – Fact Sheet. World Health Organization 2017.
3. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of Hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. *Hepatology*. 2014;59(1):318–327.
4. Murphy DG, Sablon E, Chamberland J, et al. Hepatitis C virus genotype 7, a new genotype originating from central Africa. *J Clin Microbiol*. 2015;53(3):967–972.
5. World Health Organization. Global Hepatitis Report. Geneva: World Health Organization; 2017. World Health Organization. Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of Hepatitis C virus infection in 2015: A modelling study. *Lancet Gastroenterol Hepatol*. 2017;2(3):161–176.
6. Riou J, Ahmed MA, Blake A, et al. Hepatitis C virus seroprevalence in adults in Africa: A systematic review and meta-analysis. *J Viral Hepat*. 2016;23(4):244–255.
7. Agyeman AA, Asenso RO, Mpahre A, et al. Epidemiology of hepatitis C virus in Ghana: A systematic review and meta-analysis. *BMC Infectious Diseases*. 2016;16:391.
8. Bigna JJ, Amougou MA, Asangbeh SL, et al. Seroprevalence of hepatitis C virus infection in Cameroon: A systematic review and meta-analysis. *BMJ Open*. 2017;7(8):e015748.
9. Pratelli M, Mariglio S, Loquerco G, et al. Global epidemiology of hepatitis C virus infection: An up–date of the distribution and circulation of hepatitis C virus genotypes. *World J Gastroenterol*. 2016;22(34):7824–7840.
10. Asselah T, Hassaneine T, Waked I, et al. Eliminating hepatitis C within low–income countries – The need to cure genotypes 4, 5, 6. *J Hepatol*. 2018;68(4):814–826.
11. Daw MA, El–Bouzedi A, Ahmed MO, et al. Hepatitis C virus in North Africa: An emerging threat. *Sci World J*. 2016;2016:1–11.
12. Gededzha MP, Mphahlele MJ, Blackard JT, et al. Prevalence of NS5B resistance mutations in Hepatitis C Virus (HCV) treatment naïve South Africans. *Hepat Mon*. 2017;17(6):e14248.

Citation: Gane EJ, Charlton MR, Onyekwere CA, et al. Consensus recommendations on the diagnosis and treatment of hepatitis C virus infection in sub-Saharan Africa. *Gastroenterol Hepatol Open Access*. 2019;10(4):181–193. DOI: 10.15406/ghoa.2019.10.00380
13. Burstow NJ, Mohamed Z, Gomaa AI, et al. Hepatitis C treatment: where are we now? Int J Gen Med. 2017;10:39–52.

14. Heffernan A, Barber E, Cook NA, et al. Aiming at the global elimination of viral hepatitis: Challenges along the care continuum. Open Forum Infect Dis. 2018;5(1):1–6.

15. Assefa Y, Hill PS, Ulikpan A, et al. Access to medicines and hepatitis C in Africa: Can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Global Health. 2017;13(1):1–11.

16. Suthar AB, Harries AD. A public health approach to hepatitis C-control in low and middle-income countries. PLoS Med. 2015;12(3):e1001795.

17. http://documents.worldbank.org/curated/en/335981517329520478/pdf/123067–WP–PUBLIC–P157533–Treatment–Program–Policy–Analysis.pdf

18. Sonderup MW, Afhjælten M, Ally R, et al. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol Hepatol. 2017;2(12):910–919.

19. Vermeulen J, Park JS, Jacobson I, et al. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69(5):1178–1187.

20. HCV guidance: Recommendations for testing, managing, and treating Hepatitis C. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America 2018.

21. European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511.

22. http://www.who.int/hepatitis/publications/hepatitis–c–guidelines–2016/en/.

23. Botha JF, Kassianides C, Schneider HR, et al. South African Hepatitis C Management Guidelines 2010. South African Gastroenterol Rev. 2010;8(1):20–25.

24. https://www.who.int/news-room/fact-sheets/detail/hepatitis–c

25. Goel A, Chen Q, Chhatwal J, et al. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct–acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol. 2018;33(12):2029–2036.

26. Zeba MT, Karou SD, Sagna T, et al. HCV prevalence and co-infection with HIV among pregnant women in Saint Camille Medical Centre, Ouagadougou. Trop Med Int Health. 2011;16(11):1392–1396.

27. Kodjoh N. Fighting viral hepatitis B and C in Africa. Focus on Benin. Med Sante Trop. 2015;25(2):141–144.

28. Jamma S, Hussain G, Lau DTY. Current concepts of HBV/HCV coinfection: Coexistence, yet not necessarily in harmony. Curr Hepat Rep. 2010;9(4):260–269.

29. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: Epidemiology, clinical characteristics, viral interactions and management. Ann Gastroenterol. 2015;28(2):221–228.

30. Calvaruso V, Craxi A. HBV recurrence after HCV clearance on DAAs: Sometimes they come back. J Hepatol. 2017;67(5):898–901.

31. Aggeletopoulou I, Konstantakis C, Manolakopoulou S, et al. Risk of hepatitis B reactivation in patients treated with direct–acting antivirals for hepatitis C. World J Gastroenterol. 2017;23(24):4317–4323.

32. Mucke MM, Backus LJ, Mucke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(3):172–180.

33. Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: In whom and how? Therap Adv Gastroenterol. 2011;4(1):5–10.

34. Sofosbuvir tablets for oral use. 2018. http://documents.worldbank.org/curated/en/335981517329520478/pdf/123067–WP–PUBLIC–P157533–Treatment–Program–Policy–Analysis.pdf

35. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf

36. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf

37. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206845Orig1s000lbl.pdf

38. http://www.who.int/hepatitis/publications/hepatitis–c–guidelines–2016/en/.

39. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.

40. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628.

41. Wyles D, Britó N, Kottiih S et al. Sofosbuvir and Velpatasvir for the treatment of HCV in patients coinfected with HIV–1: An open–label, Phase 3 Study. Clin Infect Dis. 2017;65(1):6–12.

42. Yang YM, Choi EJ. Efficacy and safety outcomes of sofosbuvir–based treatment regimens for hepatitis C virus–infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag. 2017;13:477–497.

43. Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin–free regimen with Sofosbuvir and Velpatasvir is associated with high efficacy and improvement of patient–reported outcomes in patients with genotypes 2 and 3 chronic Hepatitis C: Results from Astral–2 and –3 clinical trials. Clin Infect Dis. 2016;63(8):1042–1048.

44. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.

45. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.

46. Gerber L, Estep M, Stepanova M, et al. Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection. Clin Gastroenterol Hепatol. 2016;14(1):156–164.e3.

47. Moon J, Hyland RH, Zhang F, et al. Efficacy and safety of Ledipasvir/Sofosbuvir for the treatment of chronic Hepatitis C in persons with sickle cell disease. Clin Infect Dis. 2017;65(5):864–866.

48. Gupta N, Kabuhihi J, Muvunya C, et al. Direct–acting antiviral treatment in sub-Saharan Africa: A prospective trial of Ledipasvir/Sofosbuvir for chronic Hepatitis C infection in Rwanda (the SHARED study). J Hepatol. 2018;68(18):30320–30329.

49. Lacombe K, Moh R, Chazallon C, et al. Treatment of chronic Hepatitis C GT1, 2, 4 in Africa: Final results of ANRS 12311 TAC trial. 2018:75571.

50. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir in patients coinfected with HIV–1. N Engl J Med. 2015;373(8):705–713.

51. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and Sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.

52. Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir–sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non–responsive to previous protease–inhibitor therapy: A randomised, double–blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.

53. Tao T, Jiang X, Chen Y, et al. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in patients with chronic Hepatitis C Virus Genotype 1 infection: A meta–analysis. Int J Infect Dis. 2017;55:56–71.

54. Sulkowski MS, Gardiner DF, Rodriguez–Torres M, et al. Daclatasvir plus Sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
55. Poorod F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post–liver transplantation recurrence. *Hepatology*. 2016;63(5):1493–1505.

56. Castells L, Llaneras J, Campos–varela I, et al. Sofosbuvir and Daclatasvir in Mono– and HIV–coinfected patients with recurrent Hepatitis C after liver transplant. *Ann Hepatol*. 2017;16(1):86–93.

57. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real–world cohort. *Gut*. 2016;65(11):1861–1870.

58. Kwo P, Fried MW, Reddy KR, et al. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post–liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real–world cohort. *Hepatol Commun*. 2018;2(4):354–363.

59. Foster GR, Afzhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. *N Engl J Med*. 2015;373(27):2608–2617.

60. Asahina Y, Itoh Y, Ueno Y, et al. Ledipasvir/sofosbuvir in the treatment of Japanese patients with chronic HCV genotype 2 infection. *Liver Int*. 2018;38(9):1552–1561.

61. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV–1. *N Engl J Med*. 2015;373(8):714–725.

62. Luetkemeyer AF, McDonald C, Ramgopal M, et al. 12 Weeks of Daclatasvir in combination with Sofosbuvir for HIV–HCV coinfection (ALLY–2 Study). Efficacy and safety by HIV combination antiretroviral regimens. *Clin Infect Dis*. 2016;62(12):1489–1496.

63. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic Hepatitis C infection. *N Engl J Med*. 2013;368(20):1878–1887.

64. Sulkowski MS, Naggie S, Lalezarli J, et al. Sofosbuvir and Ribavirin for Hepatitis C in patients with HIV–1 coinfection. *JAMA*. 2014;312(4):353–361.

65. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus patients co–infected with HIV (PHOTON–2): a multicentre, open–label, non–randomised, phase 3 study. *Lancet*. 2015;385(9973):1098–1106.

66. Asselah T, Bourgeois S, Pianko S, et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotype 1–6 and compensated cirrhosis or advanced fibrosis. *Liver Int*. 2018;38(3):443–450.

67. Fan H, Huang P, Tian T, et al. Efficacy and safety of sofosbuvir–containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials. *J Gastrointest Liver Dis*. 2018;27(2):159–168.

68. Nelson DR, Cooper JN, Lalezarli JP, et al. All–oral 12–week treatment with Daclatasvir plus Sofosbuvir in patients with Hepatitis C virus Genotype 3 infection: ALLY–3 Phase III Study. *Hepatology*. 2015;61(4):1127–1135.

69. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C virus Genotype 3 and advanced liver disease: A randomized Phase III Study (ALLY–3). *Hepatology*. 2016;63(5):1430–1441.

70. Hézode C, De Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use programme. *J Hepatol*. 2015;62(Suppl. 2):S265–S266.

71. Leroy V, Hézode C, Metivier S, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: Interim analysis of a French multicentre compassionate use programme. *J Hepatol*. 2016;64(2):S829.

72. Hézode C, Lebray P, De Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. *Liver Int*. 2017;37(9):1314–1324.

73. Petersen J, Welzel TM, Herzer K, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV infection in patients with decompensated cirrhosis: Results of a European multicentre compassionate use programme. *J Hepatol*. 2016;64(2):S781–S782.

74. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. *Gastroenterology*. 2015;149(6):1454–1461.

75. Feld JJ, Ramji A, Shafran SD, et al. Ledipasvir–Sofosbuvir plus Ribavirin in treatment–naive patients with Hepatitis C Virus Genotype 3 infection: An open–label study. *Clin Infect Dis*. 2017;65(1):13–19.

76. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof–of–concept, single–centre, open–label phase 2a cohort study. *Lancet Infect Dis*. 2015;15(9):1049–1054.

77. Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. *Hepatology*. 2016;64(4):1049–1056.

78. Crespo J, Calleja JL, Fernández I, et al. Real–World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. *Clin Gastroenterol Hepatol*. 2015;13(6):945–949.

79. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open–label, randomised, phase 2 trial. *Lancet Infect Dis*. 2016;16(6):685–697.

80. Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with Velpatasvir in treatment–naive noncirrhotic patients with Genotype 1 to 6 Hepatitis C virus infection: A randomized trial. *Ann Intern Med*. 2015;163(11):S18–S26.

81. Abergel A, Asselah T, Metivier S, et al. Ledipasvir–sofosbuvir in patients with Hepatitis C virus genotype 5 infection: an open–label, multicentre, single–arm, phase 2 study. *Lancet Infect Dis*. 2016;16(4):459–464.